

**Amendments to the Claims**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1 (Currently amended). An isolated polypeptide, ~~which associates with TrkA and p75 neurotrophin receptors, is a target for phosphorylation by neurotrophin and ephrin receptor tyrosine kinases, enhances neurotransmitter release, and modulates the clustering of proteins involved in ion channel formation,~~ comprising the amino acid sequence of:

(A) SEQ ID NO:2;

(B) SEQ ID NO:4;

(C) a fragment of the polypeptide of SEQ ID NO:2 comprising the N-terminal ankyrin repeats;

(D) a fragment of the polypeptide of SEQ ID NO:4 comprising the N-terminal ankyrin repeats; or

(E) ~~a functional derivative or a salt of (A), (B), (C), or (D), said functional derivative being a chemical derivative that is derivatized at functional groups which occur as side chains on amino acid residues or as the N- or C-terminal groups, wherein said fragments (C) and (D) and said functional derivatives or salt (E) have the properties of associating with TrkA and p75 neurotrophin receptors, being a target for phosphorylation by neurotrophin and ephrin receptor tyrosine~~

~~kinase, enhancing neurotransmitter release, and modulating the  
clustering of proteins involved in ion channel formation.~~

2(Original). The polypeptide of claim 1, which  
comprises the amino acid sequence of SEQ ID NO:2.

3(Original). The polypeptide of claim 1, which  
comprises the amino acid sequence of SEQ ID NO:4.

4(Original). The polypeptide of claim 1, which  
comprises the amino acid sequence of fragment (C).

Claim 5 (Cancelled).

6(Original). The polypeptide of claim 1, which  
comprises the amino acid sequence of fragment (D).

Claims 7-35 (Cancelled)